Search

Cancer Council WA has awarded a Post-Doctoral Fellowship to Dr Ben Wylie, for his project to help kids with sarcoma.

Children with aggressive brain cancers could soon have access to a significant new treatment option, using a unique antibody that stops cancer cells from repairing themselves.

The Kids Research Institute Australia researcher, Dr Anya Jones, will join some of the world’s brightest female scientists after being selected to take part in a global project to amplify the voices of women in science leadership.

A landmark study led by Dr Hetal Dholaria, The Kids Research Institute Australia researcher and Perth Children’s Hospital Oncologist, has confirmed that a “wait and watch” approach for newborns diagnosed with neuroblastoma is not only safe, but effective over the long term.

One of WA’s biggest ever philanthropic gifts will transform childhood cancer research and treatment by improving outcomes for children with cancer and discovering more effective and less toxic treatments.

New research by The Kids shows donor immune cells are highly effective at boosting the body’s response against leukaemia.

The WA Kids Cancer Centre has a suite of world-leading research projects to unlock new treatments for childhood cancers.

Anaphylaxis is a severe, potentially life-threatening allergic reaction driven primarily by the activation of mast cells. We still fail to understand factors underlying reaction severity. Furthermore, there is currently no reliable diagnostic test to confirm anaphylaxis in the emergency department.

Medulloblastoma is the most common malignant paediatric brain tumour and a leading cause of cancer-related mortality and morbidity. Existing treatment protocols are aggressive in nature resulting in significant neurological, intellectual and physical disabilities for the children undergoing treatment. Thus, there is an urgent need for improved, targeted therapies that minimize these harmful side effects.

Cancer vaccination drives the generation of anti-tumor T cell immunity and can be enhanced by the inclusion of effective immune adjuvants such as type I interferons (IFNs). Whilst type I IFNs have been shown to promote cross-priming of T cells, the role of individual subtypes remains unclear. Here we systematically compared the capacity of distinct type I IFN subtypes to enhance T cell responses to a whole-cell vaccination strategy in a pre-clinical murine model.